Communication loads on clinical staff in the emergency department

Medicare rebates are currently available for these tests. The additional cost of these new technologies should be considered in the context of the cost of diagnosis, treatment and subsequent cytological and clinical followup of biologically insignificant disease. The money saved from improved patient selection for treatment and reduced frequency and late commencement of screening would allow more resources to be allocated to enrolling women (who are currently underscreened) and to funding these new technologies.